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Understanding patterns of diabetes prevalence and diabetes-re-
lated complications across pregnancies could inform chronic dis-
ease prevention efforts. We examined adverse birth outcomes by
diabetes status among women with sequential, live singleton deliv-
eries.
Methods
We used data from the 1998–2007 Massachusetts Pregnancy to
Early Life Longitudinal Data System, a population-based cohort of
deliveries. We restricted the sample to sets of parity 1 and 2 deliv-
eries. We created 8 diabetes categories using gestational diabetes
mellitus (GDM) and chronic diabetes mellitus (CDM) status for
the 2 deliveries. Adverse outcomes included large for gestational
age (LGA), macrosomia, preterm birth, and cesarean delivery. We
computed  prevalence  estimates  for  each  outcome by  diabetes
status.
Results
We identified 133,633 women with both parity 1 and 2 deliveries.
Compared with women who had no diabetes in either pregnancy,
women with GDM or CDM during any pregnancy had increased
risk for adverse birth outcomes; the prevalence of adverse out-
comes was higher in parity 1 deliveries among women with no
diabetes  in  parity  1  and GDM in  parity  2  (for  LGA [8.5% vs
15.1%], macrosomia [9.7% vs. 14.9%], cesarean delivery [24.7%
vs 31.3%], and preterm birth [7.7% vs 12.9%]); and higher in par-
ity 2 deliveries among those with GDM in parity 1 and no dia-
betes in parity 2 (for LGA [12.3% vs 18.2%], macrosomia [12.3%
vs 17.2%], and cesarean delivery [27.0% vs 37.9%]).
Conclusions
Women with GDM during one of 2 sequential pregnancies had el-
evated risk for adverse outcomes in the unaffected pregnancy,
whether the diabetes-affected pregnancy preceded or followed it.
Introduction
Pregnancy complications not only have immediate implications
for the mother and baby, but also can be a marker for future chron-
ic disease risk. Pregnant women with diabetes are at increased risk
for  several  adverse  maternal  and  infant  outcomes  including
cesarean delivery, prolonged labor, maternal birth trauma, macro-
somia,  preterm birth,  congenital  anomalies,  and fetal  hypoxia
(1,2). The most common form of diabetes during pregnancy is
gestational diabetes mellitus (GDM), which is defined as carbo-
hydrate intolerance with first  onset  or  first  recognition during
pregnancy,  and complicates  6% to  14% of  pregnancies  in  the
United States (3). A woman who develops GDM has a recurrence
rate ranging from 30% to 84% in the subsequent pregnancy (4,5)
and has a sevenfold increased risk of later developing type 2 dia-
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betes (6). Chronic diabetes mellitus (CDM), defined as type 1 or 2
diabetes diagnosed before pregnancy, complicates approximately
1% of US pregnancies (7). One of the most common complica-
tions in diabetic pregnancies is macrosomia. Infants with macroso-
mia are at an increased risk for future metabolic diseases such as
obesity, hypertension, and type 2 diabetes, perpetuating a cycle of
poor health and chronic disease (8,9).
Elevated risk of adverse pregnancy outcomes occurs at maternal
glucose levels below those resulting in a diagnosis of GDM. The
Hyperglycemia and Adverse Pregnancy Outcome Study found
continuous relationships  between increasing maternal  glucose
levels and risk of cesarean delivery, birthweight higher than the
90th  percentile,  neonatal  hypoglycemia,  and  fetal  hyperinsu-
linemia (10). In general, glycemic control during pregnancy can
significantly reduce the risk of complications (11). The intercon-
ception period is an opportunity for prevention that could improve
both short- and long-term outcomes in the mother and child. Un-
derstanding patterns of diabetes and diabetes-related complica-
tions  during pregnancy could inform those prevention efforts.
However, epidemiologic research in this area is limited. We are
aware of only one study that examined the change in maternal dia-
betic  status between pregnancies and associated newborn out-
comes. In 20 Utah hospitals, GDM in a previous pregnancy in-
creased the risk of adverse neonatal outcomes in the subsequent
pregnancy, even in the absence of GDM and after controlling for
body mass index (BMI) (12). This study builds our previous ana-
lysis (5) of diabetes incidence and recurrence during pregnancy by
further exploring adverse birth outcomes by diabetes status across
pregnancies. We examined large-for-gestational-age (LGA) in-
fants, infants with macrosomia, cesarean deliveries, and preterm
births by diabetes status across pregnancies in a diverse popula-
tion.
Methods
We used a population-based, maternally linked birth file among
women delivering sequential live infants from 1998 through 2007
using the Massachusetts Pregnancy to Early Life Longitudinal
Data System (PELL). We restricted our analysis to singleton, con-
secutive, live-birth, parity 1 and 2 deliveries. Briefly, our data as-
certainment and linkage methods involved the following steps.
First, we ascertained all singleton deliveries in PELL to the same
mother (based on mother’s name, date of birth, and Massachusetts
Universal Hospital Identification Number [a combination of the
hospital medical record number and patient’s encrypted social se-
curity number], n = 181,030 births). Second, we further restricted
the data set to first and second parity births (n = 141,233 births).
Third, to ensure we had sequential births, we excluded question-
able birth chains (ie, in which the date of last prior birth in parity 2
did not match the date of parity 1 birth [n = 6,563]). The final data
set comprised 134,760 pairs of sequentially linked parity 1 and
parity 2 deliveries.
We identified pregnancies affected by GDM and CDM from hos-
pital delivery discharge (HD) records and birth certificate (BC)
data. For HD records, we used International Classification of Dis-
eases, Ninth Revision, Clinical Modification (ICD-9-CM) codes
648.0 (CDM, excludes GDM), and 250.0 through 250.9 (CDM
without  complications  [250.0]  or  with  complications
[250.1–250.9]). For GDM, we used code 648.8. For the BC data,
diabetes status was determined from a checked box indicating ma-
ternal CDM or GDM; more than one box could be checked. There
was no check box option for “no diabetes” (no DM).
Using a hierarchical system, we classified GDM and CDM dia-
gnoses (5). Briefly, a CDM diagnosis from either source (BC data
or HD records) resulted in being classified as CDM. For the re-
maining  records,  those  with  a  diagnosis  of  GDM from either
source were classified as GDM. Pregnancies with no diabetes dia-
gnosis from either source were classified as no DM. Using this
classification yielded a kappa statistic of 0.69 for both parity 1 and
2 pregnancies and a 98.2% and 97.6% concordance for parity 1
and parity 2 pregnancies, respectively (5). From these classifica-
tions, we created 8 categories based on combinations of diabetes
status during the 2 pregnancies: No DM/No DM, No DM/GDM,
No DM/CDM, GDM/No DM, GDM/GDM, GDM/CDM, CDM/
No DM or GDM, CDM/CDM. We considered the combination of
CDM/no DM or GDM as implausible and do not report on these in
the results.
We estimated the prevalence of 4 adverse pregnancy outcomes:
LGA, macrosomia, cesarean delivery, and preterm birth. LGA was
defined as birthweight in the 90th percentile or greater for gesta-
tional age (13). Gestational age was based on clinical estimates on
the BC data when available and on last menstrual period when un-
available.  Macrosomia was defined as birthweight higher than
4,000 g, and preterm birth was defined as less than 37 weeks com-
pleted  gestation.  Cesarean delivery  was  based on HD records
(ICD-9 669.7) or BC data. Birthweight, sex, and gestational age
were based on BC data alone.
We used descriptive statistics to describe population characterist-
ics overall and by categories of diabetes status. We computed both
unadjusted and standardized prevalence estimates for each out-
come by diabetes status category. To examine whether adjusting
for the differences in population characteristics between diabetes
status groups made a difference, we standardized the prevalence
estimates for each diabetes category to the distribution of age,
race/ethnicity, insurance status, and time between deliveries in the
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entire analysis data set using logistic regression. We restricted our
analysis to deliveries with no missing values of covariates in either
parity 1 or 2 deliveries (n = 133,633). For analyses of outcome
data, we further limited analyses to women with no missing val-
ues of that outcome in either birth.
We examined risk for the 4 outcomes in women with diabetes in
one or both pregnancies compared with women who had no dia-
betes in either pregnancy. P values for comparisons between par-
ity 1 and parity 2 deliveries were adjusted for multiple comparis-
on using the Sidak inequality (14). Because comparisons between
pairs of diabetes status categories included all possible pairwise
comparisons, we adjusted the P values for those comparisons us-
ing the Tukey-Kramer method (15). We considered a P value less
than .05 as significant. Finally, we examined prevalence of recur-
rence of adverse outcomes by diabetes category. Statistical ana-
lyses were performed using SAS software V.9 (SAS Institute Inc)
for Windows. The study protocol was reviewed and approved by
the institutional review board of the Massachusetts Department of
Health.
Results
From 1998 through 2007, we identified 133,633 women with both
parity 1 and 2 deliveries who had complete diabetes status and co-
variate data. Of these women, 6.6% had at least one diabetes-af-
fected pregnancy. For parity 1 deliveries, the mean maternal age
was 28 years (Table 1). Almost half (48.9%) of the mothers had 4
or more years of college, and about three-quarters were non-His-
panic white and had private insurance. About one in 5 mothers
were foreign-born. For parity 2 deliveries, the mean maternal age
was 30 years. The mean time between deliveries was 33 months.
From parity 1 to parity 2 deliveries, the percentage of births with
LGA, macrosomia, and cesarean deliveries increased, while per-
centage of preterm births decreased.
Maternal characteristics and pregnancy outcomes
by diabetes status
Maternal characteristics varied by categories of diabetes status
across pregnancies (data not shown). Compared with women with
no diabetes during either pregnancy, women with CDM or GDM
during either pregnancy tended to be older, less educated, other
than non-Hispanic white, and foreign-born. Standardizing our res-
ults did not change any of the subsequent findings. Therefore, for
the rest of the results, we present the unstandardized findings.
We summarize findings about pregnancy outcomes according to
diabetes status categories.
1. No diabetes during either pregnancy. Compared with women
with no diabetes during either pregnancy (no DM/no DM), wo-
men with GDM or CDM during any pregnancy had higher preval-
ence of all adverse pregnancy outcomes (all were significant ex-
cept LGA parity 1, GDM/no DM; LGA parity 2, no DM/CDM;
macrosomia parity 1, GDM/no DM and GDM/CDM; macrosomia
parity 2, no DM/GDM and no DM/CDM) (Table 2). Restricting
LGA births to term deliveries did not substantially change preval-
ence estimates (data not shown). Women with CDM or GDM dur-
ing either pregnancy also had higher percentage of deliveries at
less than 37 weeks completed gestation than women with no dia-
betes during either pregnancy (Table 2).
Compared with women who had no diabetes during either preg-
nancy (no DM/no DM), women who had no DM during parity 1
but GDM (no DM/GDM) or CDM (no DM/CDM) during parity 2
pregnancies had higher prevalence of adverse outcomes in parity 1
(for LGA [8.5% vs 15.1% or 13.8%], macrosomia [9.7% vs 14.9%
or 14.1%], cesarean delivery [24.7% vs 31.3% or 38.3%], preterm
birth [7.7% vs 12.9% or 14.5%]) (Table 2). Similarly, compared
with women with no diabetes (no DM/no DM), women who had
no diabetes during parity 2 pregnancy but GDM during parity 1
pregnancy (GDM/no DM) had higher prevalence of adverse out-
comes during parity 2 pregnancy (for LGA [12.3% vs 18.2%],
macrosomia [12.3% vs. 17.2%], and cesarean delivery [27.0% vs.
37.9%]).
2. Outcomes between parity 1 and parity 2 pregnancy. The preval-
ence of LGA, macrosomia, and cesarean delivery increased from
parity 1 to parity 2 deliveries in most diabetes groups (significant
only for GDM/no DM, GDM/GDM, and CDM/CDM for LGA and
macrosomia) (Table 2). By contrast, the prevalence of preterm
birth was lower in parity 2 than parity 1 deliveries in all diabetes
categories, but was significant only for those in the no DM/GDM,
GDM/no DM, and GDM/CDM categories.
3. GDM during parity 1 pregnancy. Among those with GDM dur-
ing parity 1 pregnancy, those who had GDM/no DM had the low-
est prevalence for each of the outcomes examined, in both parity 1
and parity 2 deliveries (Table 2). Women who had GDM/GDM
had the next highest prevalence, and women who had GDM/CDM
had the highest prevalence in both parity 1 and parity 2, although
not all values were significant. Women who had GDM/CDM had
higher  prevalence  of  adverse  outcomes  than  women who had
GDM/GDM (significant for all outcomes only in parity 2 [data not
shown]).
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Recurrence of adverse outcomes
The overall likelihood of repeat LGA and macrosomia was 40.5%
and 37.8%, respectively (Table 3). However, for women who had
CDM/CDM, the likelihood of  repeat  was 70.2% for  LGA and
64.3% for macrosomia (both significantly different from No DM/
No DM). Repeat cesarean delivery overall was 86.0% and was
high across all groups. Among women with a cesarean delivery in
parity 1, women who had a combination of GDM or CDM during
both pregnancies had the highest prevalence of repeat cesarean de-
livery (91.8%–95.2%) (all significantly different from No DM/No
DM). Women who had no diabetes during either pregnancy had
the lowest prevalence of repeat cesarean delivery (85.5%). Among
women who had a preterm birth in parity 1, women who had a
combination of GDM or CDM during both pregnancies had the
highest prevalence of a repeat preterm birth (23.8%–40.3%) (sig-
nificantly different from No DM/No DM only for CDM/CDM).
Women who had no diabetes during either pregnancy had the low-
est prevalence of a recurrent preterm delivery (20.4%).
Discussion
Our findings show that adverse pregnancy outcomes were most
prevalent for deliveries in which the mother had diabetes during
both pregnancies, especially among those with CDM during both
pregnancies. In addition, women with diabetes during either of
their pregnancies had higher adverse outcomes in both the unaf-
fected and affected pregnancies than did women without diabetes
during either pregnancy.  For example,  women who developed
GDM only during their parity 2 pregnancy had a higher preval-
ence of adverse outcomes during the parity 1 pregnancy than wo-
men with no diabetes during either pregnancy. Furthermore, hav-
ing any diabetes and any poor outcome during parity 1 pregnancy
nearly doubles the likelihood of a repeat poor pregnancy outcome
in the next pregnancy, even if diabetes is absent during parity 2
pregnancy. Standardizing for age, race/ethnicity, insurance status,
and time between deliveries did not change our findings, suggest-
ing that the differences cannot be explained by changes in these
selected maternal characteristics across pregnancies.
Our findings are consistent with those of the Utah study (12) that
showed a history of GDM without recurrence may still confer an
increased risk of LGA, even after adjustment for prepregnancy
BMI. Several possible explanations exist for this increased risk
even without a formal GDM diagnosis. Screening tests for GDM
are imperfect and can miss women with abnormal glucose toler-
ance (16). Increased glucose levels not meeting the threshold for a
GDM  diagnosis  are  also  associated  with  adverse  outcomes
(17,18). Therefore, women with GDM during one pregnancy may
have higher glucose levels during other pregnancies. Other factors
such as prepregnancy BMI and gestational weight gain (not meas-
ured in our study) are strongly associated with LGA independent
of diabetes. Excess gestational weight gain (including women with
normal prepregnancy weight) contributes to more than 30% of
LGA births and is a predictor of LGA even in the absence of dia-
betes (19). Women should be encouraged to maintain a healthy
BMI before pregnancy and gain weight appropriately during preg-
nancy to reduce the odds of having adverse pregnancy outcomes.
Women with a BMI of 30 kg/m2 or higher should be offered and
referred to intensive, multicomponent behavioral interventions
(20). Furthermore, to prevent excess gestational weight gain, all
women should be counseled on appropriate diet and exercise dur-
ing pregnancy (21).
The National Institute of Health Consensus Conference on Dia-
gnosing GDM raised concern about increasing cesarean delivery
rates among women with GDM (22). Having GDM may influence
clinical decision making (eg, women with diabetes are at risk for
having large babies) and increase the likelihood of a cesarean de-
livery (23). Medically indicated cesarean delivery rates are higher
for women with GDM than for  women without diabetes (24). Our
data show that cesarean deliveries increased in those deliveries
with diabetes in both pregnancies, which may be due to medically
indicated deliveries, but this finding needs further exploration to
differentiate between elective and medically indicated deliveries.
We found that the prevalence of preterm birth decreased between
parity 1 and 2 deliveries among women who had GDM or CDM
during either pregnancy, although repeat preterm birth was highest
in women who had diabetes during both pregnancies. This finding
is inconsistent with the Utah study that reported an increased risk
of preterm birth across all categories of diabetes, although this as-
sociation disappeared when restricting the sample to parity 1 and 2
deliveries, similar to our study (12). Differences in findings could
be due to demographic factors such as having an older and more
ethnically diverse population in Massachusetts. In Utah, only 3%
of women had GDM, and the population is predominantly non-
Hispanic white. Other reasons that may account for these differ-
ences include changes in clinical practice and a shift in timing of
delivery leading to fewer postdate deliveries and fewer late pre-
term and early-term deliveries (25). Finally, preeclampsia may
also play a role; a primary risk factor for preeclampsia is nullipar-
ity, which increases the risk of preterm birth (26).
Although women with GDM are at increased risk for CDM (6),
progression to CDM may be reduced with lifestyle interventions.
Several randomized trials have demonstrated that weight loss and
increased physical activity reduce the risk for CDM in high-risk
women,  including  those  with  a  history  of  GDM  (27–29).
However, all of these influential interventions were delivered later
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in life and did not focus on the inter-conception period. Because
women with GDM during their parity 1 pregnancy have a risk of
recurrence during future pregnancies approaching 50%, reducing
BMI early in these high-risk women not only reduces risk of fu-
ture CDM (28–30), but also has the added benefit of reducing dia-
betes-related adverse outcomes during future pregnancies.
A strength of this study was that we used data from a large, popu-
lation-based cohort of women to examine adverse pregnancy out-
comes by diabetes status across pregnancies. However, our study
has limitations. First, designation of sequential parity 1 and 2 de-
liveries may be subject to misclassification error among delivery
pairs. However, such misclassification is likely nondifferential.
Second, administrative data may underestimate the true preval-
ence of GDM and CDM diagnoses. Previous research comparing
administrative data with medical records report sensitivities for
birth certificate data ranging from 46% to 83% for GDM and 47%
to 52% for CDM (31). Sensitivities for hospital discharge data
ranged from 71% to 81% for GDM and 78% to 95% for CDM.
Specificities for both sources are above 98%. Third, we did not
have data on maternal BMI, a predictor of both GDM and CDM;
therefore, we were unable to examine its additional effects. Fi-
nally, our findings may not be generalizable to populations that
differ from the Massachusetts population.
Understanding patterns  of  DM and DM-related complications
across pregnancies could inform chronic disease prevention ef-
forts. Both CDM and GDM are risk factors for adverse pregnancy
outcomes.  Although infants born to women with CDM during
both pregnancies had the highest risk for adverse outcomes, in-
fants of women with any history of diabetes during pregnancy still
had elevated risk for adverse outcomes in the unaffected preg-
nancy, regardless of whether the diabetes-affected pregnancy pre-
ceded or followed the unaffected pregnancy. These findings sug-
gest a need to carefully monitor women with a history of GDM
during a previous pregnancy, regardless of diabetes status during
the current pregnancy. To help prevent future development of dia-
betes and recurrence of adverse outcomes, women should be en-
couraged to maintain a healthy BMI before and after pregnancy
and to avoid excessive gestational weight gain.
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Tables
Table 1. Maternal Characteristics and Pregnancy Outcomes of Study Population (N = 133,633), by Parity at Delivery, Massachu-
setts, 1998–2007









Mean age, y 27.6 30.4
Education (years completed)
<High school diploma (<12) 11.8 7.8
High school diploma (12) 19.6 21.2
Some college (<4) 19.7 20.9
College degree or more (≥4) 48.9 50.1
Race/ethnicity
Non-Hispanic white 76.7 77.0
Non-Hispanic black 5.4 5.5
Hispanic 9.8 9.6
Asian 6.2 6.2











Mean no. of months between deliveries 33.2
Abbreviations: LGA, large for gestational age.
a Values are reported as percentages unless otherwise indicated.
(continued on next page)
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(continued)
Table 1. Maternal Characteristics and Pregnancy Outcomes of Study Population (N = 133,633), by Parity at Delivery, Massachu-
setts, 1998–2007
Characteristic/Outcome Parity 1 Deliverya Parity 2 Deliverya
Pregnancy Outcome
LGA (≥90th percentile; gestational age, 30–44 wks) 8.9 12.8
Macrosomia (>4,000 g) 9.9 12.6
Cesarean delivery 25.5 28.0








Mean gestational age, weeks 39.1 38.9
Abbreviations: LGA, large for gestational age.
a Values are reported as percentages unless otherwise indicated.
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Table 2. Prevalence of Pregnancy Outcomes, by Diabetes Status, in Linked Parity 1 and 2 Delivery Pairs, Massachusetts,
1998–2007a
Statistic Total
1 2 3 4 5 6 7 8



















n 131,438 122,800 3,202 434 1,892 1,911 204 426 569
Parity 1 8.9 8.5 15.1b 13.8b 9.8 13.8b,d 17.7b,d 12.2 23.6b
Parity 2 12.8 12.3c 16.3b 14.5 18.2b,c 22.4b,c,d 28.9b,d 18.8b 38.7b,c
Macrosomia (>4,000 g)
n 133,376 124,542 3,292 454 1,923 1,935 207 433 590
Parity 1 9.9 9.7 14.9b 14.1b 10.5 12.8b 14.0 12.0 19.0b
Parity 2 12.6 12.3c 14.1 12.8 17.2b,c 19.4b,c 24.6b,d 17.1 30.2b,c
Cesarean delivery
n 133,435 124,596 3,294 454 1,922 1,938 207 434 590
Parity 1 25.4 24.7 31.3b 38.3b 35.7b 39.2b 42.0b 34.1b 56.8b
Parity 2 28.0 27.0c 38.3b 44.7b 37.9b 45.2b,d 55.6b,d 40.1b 65.4b
Preterm birth (<37 wks)
n 133,445 124,604 3,294 454 1,924 1,938 207 434 590
Parity 1 8.0 7.7 12.9b 14.5b 10.3b 10.6b 18.4b,d 12.0b 21.0b
Parity 2 7.1 6.9c 9.2b,c 13.4b 7.1c 9.1b 9.2c 11.1b 18.0b
Abbreviations: CDM, chronic diabetes mellitus; DM, diabetes mellitus; GDM, gestational diabetes mellitus; LGA, large for gestational age.
a Sample sizes (ie, n) are counts of sequential pairs of births. Standardization did not change estimates based on logistic models adjusted for the following covari-
ates: mother’s age, race, insurance status, and time between deliveries; therefore, unstandardized estimates are presented.
b P < .05 compared with No DM/No DM (adjusted for multiple comparisons).
c P < .05 compared with parity 1 within the same column (adjusted for multiple comparisons).
d P < .05 compared with GDM/No DM (adjusted for multiple comparisons).
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Table 3. Prevalence of Repeat Pregnancy Outcomes, by Diabetes Status, Massachusetts, 1998–2007a
Statistic Total
1 2 3 4 5 6 7 8


















Repeat LGA (≥90th percentile)
n 11,664 10,448 484 60 186 264 36 52 134
Prevalence 40.5 39.6 39.1 38.3 47.3 55.7b 61.1 57.7 70.2b
Repeat macrosomia (>4,000 g)
n 13,257 12,061 491 64 201 247 29 52 112
Prevalence 37.8 37.2 34.4 34.4 45.3 52.6b 51.7 50.0 64.3b
Repeat cesarean delivery
n 33,949 30,729 1,031 174 686 759 87 148 335
Prevalence 86.0 85.5 90.5b 89.1 88.9b 91.8b 93.1b 89.2 95.2b
Repeat preterm birth (<37 wks)
n 10,704 9,596 424 66 198 206 38 52 124
Prevalence 20.8 20.4 21.7 31.8 17.7 23.8 29.0 23.1 40.3b
Abbreviations: CDM, chronic diabetes mellitus; DM, diabetes mellitus; GDM, gestational diabetes mellitus; LGA, large for gestational age.
a Sample sizes (ie, n) are counts of sequential pairs of births. Standardization did not change estimates based on logistic models adjusted for the following covari-
ates: mother’s age, race, insurance status, and time between deliveries; thus unstandardized estimates presented.
b P < .05 compared with No DM/No DM (adjusted for multiple comparisons).
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